Recent Research Analysts’ Ratings Updates for Incyte (INCY)

A number of research firms have changed their ratings and price targets for Incyte (NASDAQ: INCY):

• 9/1/2026 – Incyte had its “market perform” rating reaffirmed by BMO Capital Markets.
• 8/29/2026 – Incyte was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/24/2026 – Incyte was upgraded by TD Cowen to “strong-buy”.
• 8/20/2026 – Incyte had its “buy” rating reaffirmed by Benchmark Co..
• 8/20/2026 – Incyte is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $152.00 price target on the stock.
• 8/20/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $150.00 price target on the stock.
• 8/17/2026 – Incyte had its price target raised by Piper Sandler from $110.00 to $130.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Incyte had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $104.00 price target on the stock.
• 8/4/2026 – Incyte had its price target raised by Mizuho from $121.00 to $137.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Incyte had its “buy” rating reaffirmed by Citigroup Inc..
• 8/3/2026 – Incyte had its price target raised by Leerink Partners from $131.00 to $155.00. They now have an “outperform” rating on the stock.
• 8/1/2026 – Incyte was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/29/2026 – Incyte was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 7/29/2026 – Incyte had its price target raised by Royal Bank Of Canada from $99.00 to $109.00. They now have a “sector perform” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by Guggenheim from $136.00 to $150.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Incyte was given a new $119.00 price target by Morgan Stanley.
• 7/29/2026 – Incyte had its price target raised by Barclays PLC from $134.00 to $139.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by BMO Capital Markets from $112.00 to $130.00. They now have a “market perform” rating on the stock.
• 7/29/2026 – Incyte had its price target raised by HC Wainwright from $140.00 to $150.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Incyte was given a new $145.00 price target by Stifel Nicolaus.
• 7/28/2026 – Incyte had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $120.00 price target on the stock.
• 7/23/2026 – Incyte had its price target raised by Morgan Stanley from $103.00 to $104.00. They now have an “equal weight” rating on the stock.
• 7/23/2026 – Incyte had its price target raised by JPMorgan Chase & Co. from $105.00 to $110.00. They now have a “neutral” rating on the stock.
• 7/21/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 7/15/2026 – Incyte had its “market perform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright.
• 7/14/2026 – Incyte had its price target raised by Barclays PLC from $117.00 to $134.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Incyte had its price target raised by BMO Capital Markets from $94.00 to $112.00. They now have a “market perform” rating on the stock.

Insider Buying and Selling at Incyte

In related news, insider Pablo J. Cagnoni sold 10,801 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares in the company, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick A. Mayes sold 41,899 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the transaction, the executive vice president owned 61,441 shares of the company’s stock, valued at approximately $7,339,741.86. This represents a 40.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company’s stock.

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology.

Incyte’s commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling.